Molecular basis of the anti‑hyperglycemic activity of RA‑3 in hyperlipidemic and streptozotocin‑induced type 2 diabetes in rats

Simple item page
dc.contributor.authorMabhida, Sihle Ephraimen_ZA
dc.contributor.authorJohnson, Rabiaen_ZA
dc.contributor.authorNdlovu, Musawenkosien_ZA
dc.contributor.authorLouw, Johanen_ZA
dc.contributor.authorOpoku, Andrewen_ZA
dc.contributor.authorMosa, Rebamang Anthonyen_ZA
dc.date.accessioned2021-11-09T08:57:06Z
dc.date.available2021-11-09T08:57:06Z
dc.date.issued2019
dc.descriptionCITATION: Mabhida, S. E., et al. 2019. Molecular basis of the anti‑hyperglycemic activity of RA‑3 in hyperlipidemic and streptozotocin‑induced type 2 diabetes in rats. Diabetology and Metabolic Syndrome, 11:27, doi:10.1186/s13098-019-0424-z.
dc.descriptionThe original publication is available at https://dmsjournal.biomedcentral.com
dc.description.abstractBackground: Insulin resistance is a hallmark of type 2 diabetes mellitus (T2DM) and the underlying cause of various metabolic changes observed in type 2 diabetic patients. This study investigated the molecular basis of the antihyperglycemic activity of the lanosteryl triterpene (RA-3), from Protorhus longifolia stem bark, in hyperlipidemic and streptozotocin (STZ)-induced T2DM in rats. Methods: The high-fat diet fed (HFD) and STZ-induced T2DM in rat model was used to evaluate the anti-hyperglycemic activity of RA-3. The hyperlipidemic rats received a single intraperitoneal injection of STZ (35 mg/kg body weight) to induce T2DM. The experimental animals received a daily oral single dose of RA-3 (100 mg/kg body) for a period of 28 days, whiles the control group received distilled water only. The animals were euthanized, and skeletal muscle was collected for protein (IRS-1, AKT, GSK and GLUT 4) expression analysis. Western blot confirmed expression of the proteins. Results: Treatment of the diabetic animals with the RA-3 showed marked reduction in fasting plasma glucose levels in comparison to the untreated diabetic group animals. A significant decrease in p-GSK-3β and p-AKT expression was observed, whereas the expression of IRS-1ser307 were increased when compared to the diabetic control group. This effect was ablated upon treatment with RA-3 and this was concomitant to an observed increase in GLUT 4 expression. Conclusions: The results obtained in the present study strongly suggested that the anti-hyperglycemic effect of RA-3 could partly be associated with its ability to improve cellular glucose uptake in muscle tissue from T2DM.en_ZA
dc.description.urihttps://dmsjournal.biomedcentral.com/articles/10.1186/s13098-019-0424-z
dc.description.versionPublisher's version
dc.format.extent5 pagesen_ZA
dc.identifier.citationMabhida, S. E., et al. 2019. Molecular basis of the anti‑hyperglycemic activity of RA‑3 in hyperlipidemic and streptozotocin‑induced type 2 diabetes in rats. Diabetology and Metabolic Syndrome, 11:27, doi:10.1186/s13098-019-0424-z
dc.identifier.issn1758-5996 (online)
dc.identifier.otherdoi:10.1186/s13098-019-0424-z
dc.identifier.urihttp://hdl.handle.net/10019.1/123398
dc.language.isoen_ZAen_ZA
dc.publisherBMC (part of Springer Nature)
dc.rights.holderAuthors retain copyright
dc.subjectStreptozotocinen_ZA
dc.subjectHyperglycemiaen_ZA
dc.subjectLanosteryl triterpeneen_ZA
dc.subjectHigh-fat dieten_ZA
dc.subjectProtorhus longifoliaen_ZA
dc.subjectHyperlipidemiaen_ZA
dc.subjectType 2 diabetesen_ZA
dc.titleMolecular basis of the anti‑hyperglycemic activity of RA‑3 in hyperlipidemic and streptozotocin‑induced type 2 diabetes in ratsen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
mabhida_molecular_2019.pdf
Size:
904.98 KB
Format:
Adobe Portable Document Format
Description:
Download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Medical Physiology)